Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07391605 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Descartes-08 in Autoantibody Myositis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites revised (4)v6 See this version in full on ClinicalTrials.gov ↗
  2. Study sites: 2 to 4v5
  3. Primary completion pushed from Nov 2026 to Nov 2027 Recruitment opened · Completion pushed from May 2027 to May 2028 · Study sites: 0 to 2 · 1 morev4 Show 4 more changesShow less
    • Recruitment opened
    • Completion pushed from May 2027 to May 2028
    • Study sites: 0 to 2
    • Start date: Jun 30, 2026 to Apr 28, 2026
  4. Start date: Mar 1, 2026 to Jun 30, 2026v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy, safety and tolerability of an autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA) in patients with autoantibody-mediated myositis, including antisynthetase syndrome (ASyS) and dermatomyositis (DM).
Trial Details
NCT Number NCT07391605
Lead Sponsor Cartesian Therapeutics
Conditions Antisynthetase Syndrome
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov